NorthWest Biotherapeutics Inc (NWBO)

[GermanCol]

Whatever they saw was not an issue with DCVax, because the plan for the trial was to have 232 patients randomized to DCVax and 116 to placebo and it ended with the same 232 randomized to DCVax and only 99 to placebo. So the 17 not recruited where taken out of the placebo arm. Actually what they did was send all the last patients to DCVax. Opposite to what you are trying to infer, it is a very positive sign because they accelerated DCVax recruitment and didn't recruit all placebo patients. And maybe, just maybe, the reason is that the external control arms where starting to be seen as an option with the crossover and pseudoprogression issues that were leaving the trial without a placebo arm, so they didn't want to continue sending patients to placebo, and decided to send all of them to a treatment that was clearly working.

*English is not my native language.